For UK pharmaceutical and life sciences leaders
Waiting for NICE before engaging the market is costing you a year
NICE guidance is necessary but not sufficient. Companies that delay clinical and commissioner engagement until after appraisal routinely arrive well behind those that build the groundwork early, with peak-year revenue to match.
Two minutes. Solva follows up with specific pre-NICE engagement options.
- Product launches are delayed by 12-18 months post-NICE approval
- Suboptimal market uptake despite positive NICE guidance
- Frustration among sales and market access teams due to lack of clinician engagement
- Competitors gain first-mover advantage by establishing earlier relationships
- Inefficient resource allocation in market access and commercial teams
- Increased pressure on launch teams to accelerate uptake post-NICE
- Significant loss of peak-year revenue due to delayed market access
- Reduced return on investment (ROI) for R&D expenditure
- Delayed patient access to innovative treatments
- Suboptimal health outcomes for patients who could benefit from earlier intervention
- Perception of the company as slow to market or unresponsive to patient needs
- Damage to relationships with key opinion leaders and patient advocacy groups
No verified UK data available for 60% higher uptake due to parallel clinical engagement.
Source: N/A
Frequently asked questions
Why does this problem persist?
NICE guidance is necessary but not sufficient for UK commercial success. Companies that wait for NICE before engaging clinicians and commissioners are 12 to 18 months behind those that build clinical relationships in parallel.
What is the cost of leaving it unaddressed?
NICE appraisal delays can cost 3-6 months of market access and peak-year revenue. (Carnall Farrar, 2026)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.